OpGen

OpGen Assets per Share

The Total Assets per Share of OpGen (OPGN) as of Oct 23, 2026 is 3.75 USD. In the previous year, Total Assets per Share was 0.97 USD — a change of 285.85% (higher).

Assets per Share

3.75USD

YoY

285.85%

Last updated:

Total Assets per Share of OpGen is 2025 3.75 USD. Total Assets per Share of OpGen was 2024 0.97 USD. It decreases by 285.85% higher compared to the previous year.

The OpGen Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
0.88 USD
Jan 1, 2019
1.03 USD
Jan 1, 2020
4.90 USD
Jan 1, 2021
7.06 USD
Jan 1, 2022
2.54 USD
Jan 1, 2023
0.19 USD
Jan 1, 2024
0.97 USD
Jan 1, 2025
3.75 USD
The OpGen Assets per Share history
YEARAssets per ShareYoY
3.75USD+285.85%
0.97USD+423.98%
0.19USD-92.71%
2.54USD-63.96%
7.06USD+44.05%
4.90USD+377.37%
1.03USD+16.44%
0.88USD+35.20%
0.65USD-26.31%
0.89USD-34.72%
1.36USD+418.38%
0.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Total Assets per Share of OpGen is 3.75 USD in 2025.

Total Assets per Share of OpGen changed from 0.97 USD to 3.75 USD, representing a 285.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share OpGen since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — OpGen

All Key Metrics — OpGen